REPROCELL supports Silo Pharma with successful human tissue testing in Rheumatoid Arthritis study
24 October 2023
On 16 October 2023, Silo Pharma announced positive data for the effects of SPU-21 in inflamed human synovial tissue to inhibit the progression of rheumatoid arthritis (RA). Preclinical data from fresh human tissue “The purpose of this study...
REPROCELL Announces License Agreement with Gameto for the Advancement of its Program to Improve Assisted Fertility using iPSCs
04 October 2023
Gameto plans to use the iPSC line to advance its program, Fertilo, designed to improve IVF and egg freezing. YOKOHAMA, Japan — REPROCELL Inc. today announced that it has entered into an agreement to grant Gameto Inc., a female-led biotechno...
Bioserve Biotechnologies Partners with BioMavericks Ltd. to Expand Presence in the UK market
27 September 2023
[Hyderabad, India, 27 September 2023] – Bioserve Biotechnologies (India) Private Limited, a leader in molecular biology products, is teaming up with BioMavericks Ltd., a UK-based company. This partnership will allow Bioserve to extend its m...
Innovation Unleashed: REPROCELL's Q1 Recap and Insights
13 July 2023
As REPROCELL emerges from the first quarter of 2023-24, we are thrilled to present a snapshot of the activities and achievements that have set the stage for a productive year. From the launch of our new Pharmacology-AI service to winning a ...
Vernal Biosciences Announces Partnership With REPROCELL: Exclusive Distributorship in Japan for mRNA and LNP Formulation Services
11 July 2023
COLCHESTER, VERMONT and YOKOHAMA, Japan, 11 July 2023 – Vernal Biosciences, a leader in mRNA and LNP manufacturing, and REPROCELL Inc., Japan’s first induced pluripotent stem cell (iPSC) company, have partnered to provide mRNA services in J...
Joint Research Agreement with Keio University on Tumor-Infiltrating Lymphocyte Therapy for Cervical Cancer
28 June 2023
We are pleased to announce that REPROCELL has entered into a joint research agreement with Keio University regarding “transfer of technology for the production of Tumor Infiltrating Lymphocytes (TIL) for Advanced Medicine B - a phase II cli...
Simplifying AI data analysis for scientists – as REPROCELL, IBM and STFC Hartree Centre successfully launch Pharmacology-AI platform
01 June 2023
01 June 2023, Glasgow, UK and Daresbury, UK: REPROCELL today announces the launch of a new commercial service, Pharmacology-AI. The launch follows the completion of one of the first EXCELERATE projects, by the Hartree National Centre for Di...
[PRESS RELEASE] Announcement of Results of Phase II Clinical Trial in Japan for Stemchymal®, a Regenerative Medicine Product for Spinocerebellar Ataxia
25 May 2023
Yokohama Japan, 25 May 2023: We are pleased to announce the results of the Phase II clinical trial in Japan (protocol number: RS-01) of our regenerative medicine product Stemchymal® (allogeneic adipose-derived mesenchymal stem cells) for th...
REPROCELL offers mesenchymal stem cell based CDMO services to manufacture Advanced Therapies Medicinal Products
23 May 2023
Yokohama Japan, 23 May 2023: REPROCELL will now offer CDMO services to manufacture Advanced Therapies Medicinal Products (ATMPs) generated from mesenchymal stem cells (MSC) through a partnership with Histocell. REPROCELL’s subcontracting pa...
End of Q4 update from REPROCELL (2022-23)
04 May 2023
Did you know that REPROCELL is celebrating its 20th anniversary this year? If you missed the commemorative letter from our CEO we have included a link below - plus everything else we’ve been up to since the start of 2023. Celebrating the 20...